Benefits
A drug diluent used according to the receiving medicine’s instructions, not a treatment by itself.
Named U.S. presentation only; selected label sections.
Peptide library
Bacteriostatic Water
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The named U.S. product label is the appropriate source for its approved use, contraindications and handling. A medicine-like elimination half-life is not applicable to this diluent. Its handling instructions do not establish the pharmacokinetics of a drug mixed with it. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.
About this assessment
Named U.S. product label sections assessed.
Product-specific editorial extraction. Complete clinical review and clinician sign-off remain pending; other jurisdictions are not inferred.
Editorial assessment · 2026-09-07
Who was studied
The population specified by this product label; other indications and jurisdictions remain outside this check.
What the sources found
A drug diluent used according to the receiving medicine’s instructions, not a treatment by itself.
Regulatory scope
U.S. label record for NDA018802. This does not confer authorization on other products using the ingredient name.
What remains unknown
Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.
How it works
HealthFirst/Hospira Bacteriostatic Water for Injection, 30 mL
Consult the product label for pharmacology. A mechanism does not extend its approved indications.
Approved product exists
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Reported adverse effects
- Benzyl alcohol can harm neonates. Intravenous administration without an appropriate solute can cause hemolysis.
Named U.S. presentation only; selected label sections.
Contraindications
- This benzyl-alcohol-containing diluent must not be used in neonates, for fluid replacement, or for epidural/spinal anesthesia. It must be made approximately isotonic for administration as directed by the receiving medicine.
Approved product exists
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Sources used for this snapshot
Claim-by-claim evidence
Adverseeffects
Benzyl alcohol can harm neonates. Intravenous administration without an appropriate solute can cause hemolysis.
Named U.S. presentation only; selected label sections.
Storage
This presentation: 20–25°C. Its storage does not establish the shelf life of a medicine mixed with it.
Named U.S. presentation only; selected label sections.
Pharmacokinetics
A medicine-like elimination half-life is not applicable to this diluent. Its handling instructions do not establish the pharmacokinetics of a drug mixed with it.
Named U.S. product only; label revision 20250108. Educational extraction, not complete clinical review.
Contraindications
This benzyl-alcohol-containing diluent must not be used in neonates, for fluid replacement, or for epidural/spinal anesthesia. It must be made approximately isotonic for administration as directed by the receiving medicine.
Named U.S. product only; label revision 20250108. Educational extraction, not complete clinical review.
References
HealthFirst/Hospira Bacteriostatic Water for Injection, 30 mL. U.S. structured product label, effective 20250108. Selected sections only.
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.